DOP2023000060A - Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención - Google Patents

Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención

Info

Publication number
DOP2023000060A
DOP2023000060A DO2023000060A DO2023000060A DOP2023000060A DO P2023000060 A DOP2023000060 A DO P2023000060A DO 2023000060 A DO2023000060 A DO 2023000060A DO 2023000060 A DO2023000060 A DO 2023000060A DO P2023000060 A DOP2023000060 A DO P2023000060A
Authority
DO
Dominican Republic
Prior art keywords
inhibitors
line
treat diseases
diseases background
subject
Prior art date
Application number
DO2023000060A
Other languages
English (en)
Inventor
Sturino Claudio
Doshi Malay
G Cordingley Michael
Weber Eckard
Original Assignee
Transposon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transposon Therapeutics Inc filed Critical Transposon Therapeutics Inc
Publication of DOP2023000060A publication Critical patent/DOP2023000060A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La presente descripción proporciona métodos para tratar o prevenir una enfermedad, trastorno, o afección en un sujeto que los necesita, en donde los métodos comprenden administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto de la Fórmula I: o una sal o un solvato farmacéuticamente aceptable de este, o un tautómero de este, en donde R1, R2, y B se definen como se expone en la especificación.
DO2023000060A 2020-09-23 2023-03-23 Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención DOP2023000060A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082185P 2020-09-23 2020-09-23
US202163161055P 2021-03-15 2021-03-15
PCT/US2021/051716 WO2022066880A1 (en) 2020-09-23 2021-09-23 Line-1 inhibitors to treat disease

Publications (1)

Publication Number Publication Date
DOP2023000060A true DOP2023000060A (es) 2023-09-29

Family

ID=80845827

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000060A DOP2023000060A (es) 2020-09-23 2023-03-23 Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención

Country Status (12)

Country Link
US (1) US20230414616A1 (es)
EP (1) EP4216962A1 (es)
JP (1) JP2023549979A (es)
KR (1) KR20230107543A (es)
AU (1) AU2021347247A1 (es)
CA (1) CA3193512A1 (es)
CL (1) CL2023000857A1 (es)
DO (1) DOP2023000060A (es)
IL (1) IL301564A (es)
MX (1) MX2023003332A (es)
TW (1) TW202228723A (es)
WO (1) WO2022066880A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240017910A (ko) * 2021-06-04 2024-02-08 트랜스포손 테라퓨틱스, 인코포레이티드 인지 향상제로서 line-1 억제제
WO2023178133A1 (en) * 2022-03-15 2023-09-21 Rome Therapeutics, Inc. Compounds and methods for treating disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117986A (en) * 1998-06-10 2000-09-12 Intergen Company, L.P. Pyrimidines linked to a quencher
US20140031250A1 (en) * 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
SG11202107145SA (en) * 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Also Published As

Publication number Publication date
CL2023000857A1 (es) 2023-11-10
US20230414616A1 (en) 2023-12-28
WO2022066880A1 (en) 2022-03-31
IL301564A (en) 2023-05-01
TW202228723A (zh) 2022-08-01
CA3193512A1 (en) 2022-03-31
KR20230107543A (ko) 2023-07-17
EP4216962A1 (en) 2023-08-02
JP2023549979A (ja) 2023-11-29
MX2023003332A (es) 2023-06-16
AU2021347247A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
CO2021015318A2 (es) Compuestos y métodos para el tratamiento de covid-19
CO2023008018A2 (es) Nuevos agentes antivirales derivados de la espiropirrolidina
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
ECSP13012964A (es) Tratamientos combinados para neoplasias hematologicas malignas
AR070299A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
UY39559A (es) Compuestos y su uso
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
CL2022000781A1 (es) Tratamientos cognitivos medicinales
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
AR125118A1 (es) Actividad antiviral de inhibidores de vps34
BR112021024835A2 (pt) Tratamento para sinuclenopatias
PH12021550471A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
UY39593A (es) Tratamiento para tumores sólidos malignos
CL2023000648A1 (es) Métodos para tratar enfermedades o afecciones mediadas por pde iv
AR122301A1 (es) Métodos para tratar los tumores del estroma gastrointestinal
CL2021001093A1 (es) Compuestos, composiciones, y métodos para modular la actividad cdk9
BR112022005980A2 (pt) Método para prevenir e/ou tratar declínio cognitivo em um sujeito cognitivamente saudável, composto, e, uso de um composto